We use cookies to see how investors use El Fondo and make its tools, data and markets better for you. You can accept or reject; essential cookies always stay on. Privacy Policy
Trades about 172% below its sector, cheaper than its peers on earnings.
FutureChem Co.,Ltd is a South Korean company dedicated to the creation and distribution of radiopharmaceutical products. Its current offerings include PDVUE, a positron emission tomography (PET) diagnostic agent for Parkinson's disease; Alzavue, used in the diagnosis of Alzheimer's disease; and [18F]FDG, a PET radiopharmaceutical primarily employed in cancer therapy. The company's development pipeline is robust, featuring 18F-FC303, a PET diagnostic for prostate cancer; 177Lu-FC705, targeting prostate cancer treatment; 18F-FMT, aimed at brain tumors; 18F-FC505, designed for atherosclerotic plaque; and 18F-FC211, another prospective treatment for Alzheimer's disease. Founded in 1999, FutureChem Co.,Ltd is headquartered in Seoul, South Korea.
Loading the full price history…
Run your own numbersPast performance is not a forecast.
Save 220100.KQ and get told when something moves.
Get updates
A clear, direct weekly summary.
Learn the fundamentals behind this asset.
A stock is a fraction of ownership in a real company. Buy one share and you own a piece (usually a tiny piece) of every desk, factory, contract and brand the company runs. The price moves because the market keeps revising what that whole pie is worth.
The price-to-earnings ratio is how much investors are paying for one dollar of a company's profit. A multiple, never an absolute. Always compared to something: a sector, a region, the company's own past.
Dividend yield is the annual income a stock or ETF pays out, expressed as a percentage of what you paid for it. It is the visible part of total return: the cash that lands in your account every quarter, and the lever most retail investors actually feel.
Market cap is shares times price. A simple formula that produces wildly unequal numbers: a single US tech name can be worth more than every company on a LATAM exchange combined.
